Log in
Enquire now
Poseida Therapeutics

Poseida Therapeutics

Poseida Therapeutics develops targeted cell therapy founded in 2014 by Eric Ostertag.

OverviewStructured DataIssuesContributors

Contents

poseida.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Immunotherapy
Immunotherapy
Cell therapy
Cell therapy
Therapeutics
Therapeutics
Biomedical engineering
Biomedical engineering
Technology
Technology
...
Location
San Diego
San Diego
0
B2X
B2C
B2C
B2B
B2B
0
CEO
‌
Mark J. Gergen
0
Founder
Eric Ostertag
Eric Ostertag
0
AngelList URL
angel.co/company/po...herapeutics
Pitchbook URL
pitchbook.com/profiles...149802-85
Legal Name
Poseida Therapeutics, Inc.
Legal classification
Corporation
Corporation
Date Incorporated
2014
Spun Out From
Transposagen Biopharmaceuticals
Transposagen Biopharmaceuticals
Number of Employees (Ranges)
201 – 5000
Email Address
info@poseida.com0
sthailing@poseida.com0
Phone Number
+185860537170
+185877931000
Number of Employees
2900
Full Address
9390 Towne Centre Drive, Suite 200 San Diego, CA 921210
CIK Number
1,661,4600
Investors
Novartis
Novartis
Rapha Capital Management
Rapha Capital Management
Longitude Capital
Longitude Capital
Tavistock Life Sciences
Tavistock Life Sciences
0
Vivo Capital
Vivo Capital
Malin Corporation
Malin Corporation
Tavistock Group
Tavistock Group
IRS Number
472,846,5480
Founded Date
2014
Total Funding Amount (USD)
333,533,230
Latest Funding Round Date
June 25, 2020
Business Model
Commerce
Stock Symbol
PSTX
Exchange
Nasdaq
Nasdaq
Board of Directors
‌
Mark J. Gergen
0
‌
John Schmid
0
‌
Cynthia Collins
0
Eric Ostertag
Eric Ostertag
0
CFO
‌
Johanna Mylet
0
Former CEO
Eric Ostertag
Eric Ostertag
Latest Funding Type
Series C
Series C
Patents Assigned (Count)
12
Wellfound ID
poseida-therapeutics
Technologies Used
CRISPR
CRISPR
Country
United States
United States

Other attributes

Company Operating Status
Active
Contact Page URL
poseida.com/company/contact/
SIC Code
2,8360
Ticker Symbol
PSTX0
Wikidata ID
Q104481456

Poseida Therapeutics is a privately held, biopharmaceutical company based in San Diego California. It leverages proprietary non-viral, gene engineering technologies to create therapeutics for illnesses with high unmet medical needs. The company is developing a wholly-owned pipeline of autologous and allogenic CAR-T product candidates, initially focused on the treatment of hematological malignancies and other solid tumors.

Poseida's leading product candidate is P-BCMA-101, an autologous CAR-T product that targets B cell maturation antigen, or BCMA, which is expressed on multiple myeloma cells. In December 2018, the company announced positive results from its first cohort of ongoing Phase 1 clinical trial. Poseida's second autologous product is P-PSMA-101, targeting cells that express prostate-specific membrane antigen, which is expressed on most prostate cancer cells. The product is being developed to treat patients with castrate-resistance prostate cancer, or CRPC, a solid tumor indication, with Phase 1 clinical trials planned in the second half of 2019.

Under the allogenic category, Poseida has P-BCMA-ALL01 and P-MUC1C-101. Derived from healthy donors, P-BCMA-ALL01 is designed to have the same inherent properties and functions of P-BCMA-101, but with the benefits of scale and administration efficiency that come from an allogenic product. The company plans to file an IND and begin Phase 1 clinical trials by late 2019 or early 2020. As for P-MUC1C-101, the product is in late-stage pre-clinical development for multiple solid tumor indications with plans for Phase 1 clinical trials in 2020.

In January 2019, Poseida Therapeutics filed documents for an IPO of $115 million.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting

Poseida Therapeutics, Inc.

https://globenewswire.com/news-release/2018/12/04/1661326/0/en/Poseida-Therapeutics-Provides-Update-on-Phase-1-Study-of-P-BCMA-101-CAR-T-Product-Candidate-at-the-2018-American-Society-of-Hematology-Annual-Meeting.html

Web

Xconomy: Poseida Therapeutics Prepares for IPO to Advance CAR-T Treatments

https://xconomy.com/san-diego/2019/01/04/poseida-therapeutics-prepares-for-ipo-to-advance-car-t-treatments/

Web

References

Find more companies like Poseida Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.